Articles related to ANTIBODY-DRUG CONJUGATES (ADCs)

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.

Explore groundbreaking trials from SABCS 2023, revealing the potential of sacituzumab govitecan and datopotamab deruxtecan in enhancing treatment paradigms for metastatic breast cancer, spotlighting pivotal advancements in antibody-drug conjugate therapy.

Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.

Explore the newest developments in lymphoma therapy with the help of this CME program, learn how effective bispecific antibodies and antibody-drug conjugates are, and fine-tune your therapeutic approaches.